Trubion Pharmaceuticals, Inc.company was founded in 1999 and is headquartered in Seattle, Washington. Trubion Pharmaceuticals, Inc., a biopharmaceutical company, engages in the development of protein therapeutic product candidates for the treatment of autoimmune and inflammatory diseases and cancer. The company, in a collaboration with Wyeth, is conducting a phase IIb clinical trial for its lead product candidate, TRU-015, for the treatment of rheumatoid arthritis. The company also offers TRU-016, a phase II/II clinical evaluation product and a novel CD37-targeted therapy for the treatment of B-cell malignancies, such as chronic lymphocytic leukemia and certain autoimmune and inflammatory disease indications. It also has collaboration agreement with Wyeth for the development and commercialization of SBI-087 for the treatment of rheumatoid arthritis and SBI-087 for the treatment of systemic lupus erythematosus, as well as other therapeutics directed to CD20, an antigen that is a validated clinical target present on B cells.

Sepracor Inc. company focuses its drug development efforts in two main therapeutic categories: respiratory and central nervous system (CNS) disorders. Its marketed products include asthma drug Xopenex, insomnia therapy Lunesta, and chronic obstructive pulmonary disease (COPD) treatment Brovana. Sepracor markets its products to primary care physicians and some specialists in the US; it also has some limited operations in Canada. It has licensed international development and commercialization rights for Lunesta to Eisai and GlaxoSmithKline. Sepracor was acquired for $2.6 billion by Japanese firm Dainippon Sumitomo Pharma in 2009.

Calyx Bio-Ventures (formerly Chromos Molecular Systems) wants you to part with that chromosome. The company is developing therapeutic products to fight diseases based on its REM (rapid expansion method) technology. The company has sold its ACE System (artificial chromosome expression) technology but retains some rights to use the ACE System for gene therapy applications. The system's potential biopharmaceutical product applications include therapies for infectious diseases and cancers. The company emerged from bankruptcy protection in late 2007 and completed its restructuring when it merged its operations into its Calyx subsidiary the following year.

The health care products subsidiary of Bayer AG, Bayer HealthCare develops and manufactures products for humans and animals. Bayer HealthCare operates through four divisions: Pharmaceuticals (represented by Bayer Schering Pharma and Bayer Healthcare Pharmaceuticals); Consumer Care (OTC medications); Animal Health (veterinary drugs); and Medical Care (diagnostic equipment makers including Diabetes Care and MEDRAD). Bayer HealthCare's better-known products include YAZ birth control pills, antibiotic Avelox, erectile dysfunction treatment Levitra, Bayer Aspirin, Alka-Seltzer, One-A-Day vitamins, and the flea preventative Advantage.

Quality Assured Services (QAS) is a direct marketer of point-of-care and self-testing diagnostic products. It distributes easy-to-use diagnostic kits directly to consumers' homes, as well as to health professionals and home health care providers. Its products include anticoagulation tests, cholesterol tests, and other products that monitor and diagnose such conditions as blood pressure, diabetes, lung function, and infectious diseases. The company also provides telemedicine support, patient management software, insurance verification, and billing services. QAS is a subsidiary of diagnostic products firm Inverness Medical Innovations.

3SBio Inc. was founded in 1993 and is based in Shenyang, the Peoples Republic of China. 3SBio Inc. is an integrated biotechnology company focused on researching, developing, manufacturing and marketing biopharmaceutical products primarily in China. The Company’s recombinant, or genetically engineered, protein-based products and product candidates are designed to address markets with unmet medical needs in nephrology, oncology, supportive cancer care, inflammation and infectious diseases. Its principal products are EPIAO and TPIAO, and its legacy products are Intefen and Inleusin. EPIAO is an injectable recombinant human erythropoietin (EPO) that is used to stimulate the production of red blood cells in patients with anemia and to reduce the need for blood transfusions. 3SBio Inc. had launched TPIAO, its internally developed protein-based therapeutic product. In addition to EPIAO and TPIAO, the Company markets two other protein-based therapeutics.

Natrol, Inc. company was founded in 1980 and is headquartered in Chatsworth, California. Natrol, Inc. manufactures and distributes nutritional products. The company offers nutritional and dietary supplements, functional herbal teas, and sports nutrition products for heart and digestive health, weight management and energy, mood and sleep support, eye and joint health, and children's and brain health. It also provides Natrol Immune Boost for the wellness of bodys immune system. In addition, the company manufactures supplements for third parties. It offers its products through retailers in the United States and subsidiaries in the United Kingdom and Hong Kong, as well as through distribution partners internationally.

Bionovo, Inc. company was founded in 2002 and is based in Emeryville, California. Bionovo, Inc. is a clinical stage drug discovery and development company focusing on women’s health and cancer. The Company designs drugs derived from botanical sources, which have mechanisms of action. The Company’s drug candidate, Menerba, represents a class of receptor sub-type selective estrogen receptor modulator (SERM) for the treatment of vasomotor symptoms of menopause, or hot flashes. The Company has designed Menerba to selectively modulate estrogen receptor beta (ERβ). In preclinical studies, Menerba inhibited tumor growth, as well as bone resorption known to cause osteoporosis, which is developed during menopause. The Company was developing BZL101, an oral anti-cancer agent for advanced breast cancer during the year ended December 31, 2008. BZL101 is designed to take advantage of the metabolism of cancer cells. BZL101 inhibits glycolysis, a metabolic pathway on which cancer cells rely.

Taconic Farms, Inc. company provides research rodents and related products and services to research facilities and medical laboratories in Asia, Europe, and North America. Taconic's rats and mice are the workhorses of the biomedical industry and specially bred to be disease-free or genetically modified to exhibit certain traits to help researchers develop new therapies for human disease. Other divisions within the company offer monoclonal antibody production, and drug- and animal-safety testing. It has operations in Denmark, Germany, and the US. Family-owned Taconic was founded in 1952 by Robert Phelan.

Pharsight wants to shorten the path to market for tomorrow's pharmaceutical breakthroughs. The company's software and consulting services aim to take some of the guesswork out of the drug development process for pharmaceutical and biotech firms, helping them choose the most promising drug candidates, to design effective clinical trials, and to keep up with regulatory reporting. Pharsight's WinNonlin and WinNonMix applications, for instance, analyze research and clinical data to help companies develop appropriate dosing regimens for clinical trials. And its consulting services help them make key strategy decisions about the future of development programs. Pharsight was acquired by Tripos in 2008.

Inviting Real Estate Agents, Job Placements Agents, Educational Institutes, Software Service Providers, Real Estate Builders, Marriage Bureaus, Travel Agents, Restaurant Owners, Health & Fitness Centers and other Local Businesses to Post a FREE Classified Advertisement on Cootera.com Classifieds Website.